In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d
- PMID: 35500263
- DOI: 10.7326/J22-0026
In high-risk outpatients with COVID-19, remdesivir reduced COVID-19-related hospitalization or all-cause death at 28 d
Abstract
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386:305-15. 34937145.
Comment on
-
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.N Engl J Med. 2022 Jan 27;386(4):305-315. doi: 10.1056/NEJMoa2116846. Epub 2021 Dec 22. N Engl J Med. 2022. PMID: 34937145 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources